Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities

Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negativel...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemzadeh, Nastran, Adibkia, Khosro, Barar, Jaleh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378097/
https://www.ncbi.nlm.nih.gov/pubmed/30788254
http://dx.doi.org/10.15171/bi.2019.01
_version_ 1783395867228635136
author Hashemzadeh, Nastran
Adibkia, Khosro
Barar, Jaleh
author_facet Hashemzadeh, Nastran
Adibkia, Khosro
Barar, Jaleh
author_sort Hashemzadeh, Nastran
collection PubMed
description Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, Trp/Kyn pathway, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors.
format Online
Article
Text
id pubmed-6378097
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-63780972019-02-20 Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities Hashemzadeh, Nastran Adibkia, Khosro Barar, Jaleh Bioimpacts Editorial Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, Trp/Kyn pathway, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors. Tabriz University of Medical Sciences 2019 2018-10-21 /pmc/articles/PMC6378097/ /pubmed/30788254 http://dx.doi.org/10.15171/bi.2019.01 Text en © 2019 The Author(s) This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Editorial
Hashemzadeh, Nastran
Adibkia, Khosro
Barar, Jaleh
Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title_full Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title_fullStr Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title_full_unstemmed Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title_short Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
title_sort indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378097/
https://www.ncbi.nlm.nih.gov/pubmed/30788254
http://dx.doi.org/10.15171/bi.2019.01
work_keys_str_mv AT hashemzadehnastran indoleamine23dioxygenaseinhibitorsinimmunochemotherapyofbreastcancerchallengesandopportunities
AT adibkiakhosro indoleamine23dioxygenaseinhibitorsinimmunochemotherapyofbreastcancerchallengesandopportunities
AT bararjaleh indoleamine23dioxygenaseinhibitorsinimmunochemotherapyofbreastcancerchallengesandopportunities

Ejemplares similares